Your session is about to expire
← Back to Search
Electrolyte Supplement
Lidocaine-ineffective ADHD: Intervention for Attention Deficit Hyperactivity Disorder (ADHD)
Phase 1 & 2
Waitlist Available
Led By Michael M Segal, MD PhD
Research Sponsored by AlkaliDx, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline and ~1 hour after intervention
Awards & highlights
Study Summary
Randomized, controlled, double-blind trial of the effect of a single dose of potassium on ADHD symptoms as measured by changes in measures of symptoms of ADHD correlated with the results of their Lidocaine Effectiveness Test.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline and ~1-2 hours later, 1 hour after intervention
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline and ~1-2 hours later, 1 hour after intervention
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Prevalence of lidocaine ineffectiveness in those with ADHD
Secondary outcome measures
Change in ADHD-RS questionnaires
Change in Clinical Global Impression Physician Completed Questionnaire
Change in scores using Quotient ADHD System
+2 moreTrial Design
4Treatment groups
Active Control
Placebo Group
Group I: Lidocaine-ineffective ADHD: InterventionActive Control1 Intervention
Single-dose potassium gluconate oral capsule intervention for ADHD subjects for whom lidocaine is ineffective
Group II: Lidocaine-effective ADHD: InterventionActive Control1 Intervention
Single-dose potassium gluconate oral capsule intervention for ADHD subjects for whom lidocaine is effective
Group III: Lidocaine-effective ADHD: PlaceboPlacebo Group1 Intervention
Single-dose placebo oral capsule intervention for ADHD subjects for whom lidocaine is effective
Group IV: Lidocaine-ineffective ADHD: placeboPlacebo Group1 Intervention
Single-dose placebo oral capsule intervention for ADHD subjects for whom lidocaine is ineffective
Find a Location
Who is running the clinical trial?
AlkaliDx, Inc.Lead Sponsor
Michael M Segal, MD PhDPrincipal InvestigatorPhenoSolve, LLC
2 Previous Clinical Trials
45 Total Patients Enrolled
Mark Mintz, MDPrincipal InvestigatorCNNH & CRCNJ
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger